 JERSEY CITY, N.J., June 09, 2021 GLOBE NEWSWIRE -- SCYNEXIS, Inc. NASDAQ: SCYX, a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that the U.S. Food and Drug Administration FDA granted BREXAFEMME ibrexafungerp tablets, five years of exclusivity extension under the Generating Antibiotic Incentives Now GAIN Act. This exclusivity will be added to any other applicable exclusivity periods, such as the five years of new chemical entity NCE exclusivity, for a combined ten-year period of regulatory exclusivity. BREXAFEMME is also protected by multiple patents, including a composition-of-matter patent covering the ibrexafungerp molecule. With patent term extension, this patent is expected to expire in 2035, providing 14 years of protection from generic competitors in the U.S. 